Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2000-05-26
2004-05-04
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093200, C424S093600, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
06730297
ABSTRACT:
TECHNICAL FIELD
The present invention relates to compositions and methods for treating diseases of the eye, and more specifically, to the use of various gene delivery vectors which direct the expression of selected gene products suitable for treating or preventing diseases of the eye and brain associated with lysosomal storage disorders and other genetic defects.
BACKGROUND OF THE INVENTION
Mucopolysaccharidoses (MPS) refer to a group of inherited lysosomal storage diseases, each of which is caused by the deficiency of a lysosomal enzyme that degrades glycosaminoglycans (GAGs). MPS patients exhibit undegraded GAGs in lysosomes, leading to lysosomal distention and progressive cellular and organ dysfunction, caused by accumulation of chondroitin, dermatan and heparan sulphate. Patients afflicted with MPS can have a variety of clinical features including short stature, progressive bone and joint abnormalities termed dysostosis multiplex, course facial features, deafness, corneal clouding, hepatosplenomegaly, mental retardation and premature death. The lysosomal storage defect can occur in the viscera, brain and skeleton, and the accumulated GAGs have a fibrillogranular appearance ultrastructurally (Vogler et al., J. Inher. Metab. Dis. 21:575-586, 1998).
One member of this disease group is a hereditary retinal disease caused by &bgr;-glucuronidase deficiency. Also known as MPS VII, it is a progressive condition, with most tissues affected including the CNS.
Canine and murine models of MPS VII have been described (Haskins et al.,
Pediatr Res
18:980-984, 1984, Birkenmeier et al.,
J Clin Invest
83:1258-1256, 1989). The MPS mouse shares many common features with human patients, including the ocular pathology (Li and Davidson,
PNAS
92:7700-7704, 1995; Volger et al.,
Am J Pathol
136:207-217, 1990). These shared features make the MPS mouse an attractive model for studying experimental treatment of a lysosomal disease. For example, cells in diseased tissues contain numerous distended lysosomes. In the brain, both neurons and cells of glial lineage are affected. In the eye, the retinal pigment epithelium (RPE) is affected.
Gene therapy has been used to treat a variety of disorders and gene transfer to the eye has been attempted using recombinant vectors such as adenovirus (Li et al.,
Invest Opthalmol Vis Sci
35:2543-2549, 1994; Borras et al.,
Gene Ther
6:515-524, 1999; Li and Davidson,
PNAS
92:7700-7704, 1995; Sakamoto et al.,
H Gene Ther
5:1088-1097, 1999) adeno-associated virus (Ali et al.,
Hum Gene Ther
9:81-86, 1998, Flannery et al.,
PNAS
94:6916-6921, 1997; Bennett et al.,
Invest Opthalmol Vis Sci
38:2857-2863, 1997; Jomary et al., Gene Ther 4:683-690, 1997, Rolling et al.,
Hum Gene Ther
10:641-648, 1999; Ali et al.,
Hum Mol Genet
5:591-594, 1996) and human immunodeficiency virus (Miyoshi et al.,
PNAS
94:10319-23, 1997; Takahashi et al.,
J Virol
73:7812-7816, 1999). Each of these viruses infect slightly different populations of cells. For example, an intravitreal injection of adenovirus infects cells only in the anterior segment of the eye, mainly the corneal endothelium and iris pigmented epithelium, while a subretinal injection results mainly in positive RPE and muller cells (Li et al.,
Invest Opthalmol Vis Sci
35:2543-2549, 1994; Li and Davidson,
PNAS
92:7700-7704, 1995; Sakamoto et al.,
H Gene Ther
5:1088-1097, 1999. AAV injected intravitreally results in transduction of the ganglion cell layer and the RPE. A subretinal injection produces positive photoreceptors, in addition to the RPE and ganglion cells (Ali et al.,
Hum Mol Genet
5:591-594, 1996). Studies with HIV injected subretinally have shown efficient transduction of the RPE and photoreceptors (Miyoshi et al.,
PNAS
94:10319-23, 1997; Takahashi et al.,
J Virol
73:7812-7816, 1999).
Recombinant retroviral gene delivery methods have been extensively utilized in other gene therapy approaches, in part due to: (1) the efficient entry of genetic material (the vector genome) into cells; (2) an active, efficient process of entry into the target cell nucleus; (3) relatively high levels of gene expression; (4) the potential to target particular cellular subtypes through control of the vector-target cell binding and the tissue-specific control of gene expression; (5) a general lack of pre-existing host immunity; (6) substantial knowledge and clinical experience which has been gained with such vectors; and (7) the capacity for stable and long-term expression.
Briefly, retroviruses are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate. Upon infection by the RNA virus, the retroviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each retrovirus. The viral DNA is then integrated pseudo-randomly into the host cell genome of the infected cell, forming a “provirus” which is inherited by daughter cells.
One type of retrovirus, the murine leukemia virus, or “MLV”, has been widely utilized for gene therapy applications (see generally Mann et al.
Cell
33:153, 1983; Cane and Mulligan,
PNAS
81:6349, 1984; and Miller et al.,
Human Gene Therapy
1:5-14, 1990). One major disadvantage of MLV-based vectors, however, is that the host range (i.e., cells infected with the vector) is limited, and the frequency of transduction of non-replicating cells is generally low.
Feline immunodeficiency virus (“FIV”)-mediated gene therapy vector systems have also been described (see, International Publication Nos. WO 99/15641 and WO 99/36511).
The present invention provides compositions and methods for treating and preventing a number of retinal and brain diseases and degenerations such as RP and AMD, using retrovirus-mediated gene transfer and, further, provides other related advantages.
SUMMARY OF THE INVENTION
The present invention provides compositions and methods for treating, preventing, or inhibiting diseases of the eye and the brain, and in particular, diseases of the eye and brain that result from iysosomal storage disease or from deficiency of retinal gene products. Within one aspect of the present invention, methods are provided for treating or preventing diseases of the eye or brain comprising the step of intravitreal administration of a gene delivery vector which directs the expression of one or more polypeptides, proteins or enzymes, such that the disease is treated or prevented. Within certain embodiments of the invention, a viral promoter (e.g., CMV), a tissue-specific promoter (e.g., opsin or RPE), or an inducible promoter (e.g., tet) is utilized to drive the expression of the polypeptide, protein or enzyme factor.
Preferred gene delivery vectors suitable for use within the present invention may be generated from retroviruses such as FIV or HIV.
Utilizing the methods and gene delivery vectors provided herein a wide variety of retinal diseases may be readily treated or prevented, including for example, macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, glaucoma, retinal detachment or injury and retinopathies. Genes encoding a wide variety of polypeptides, proteins or enzymes may be employed, including those which, when expressed, prevent or alleviate the effects of the lysosomal storage disorder. An example is &bgr;-glucuronidase.
The invention therefore relates to a method of treating or preventing retinal diseases of the eye, comprising, administering intravitreously a gene delivery vector which directs the expression of a polypeptide, protein or enzyme, such that said retinal disease of the eye is treated or prevented.
In certain embodiments, the protein, polypeptide or enzyme is selected from the group consisting of &bgr;-glucuronidase; neuraminidase; sphingomyelinase; sulfatases; arylsulfatase &bgr;; &bgr;-galactosidase; &agr;-galactosidase; ceramidase; glucocerebrosidase; &bgr;-hexosaminidase; galactosylceramidase; arylsulfatase A; &agr;-N-acetylgalactosaminidase; aspartylglycosaminidase; &agr;-L-fucosidase; &agr;-mannosidase; &bgr;-mannosid
Davidson Beverly
Dubensky, Jr. Thomas W.
Heth Jason A.
Jolly Douglas J.
Sauter Sybille L.
Blackburn Robert P.
Chen Shin-Lin
Chiron Corporation
Harbin Alisa A.
Robins Roberta L.
LandOfFree
Use of recombinant gene delivery vectors for treating or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of recombinant gene delivery vectors for treating or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of recombinant gene delivery vectors for treating or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3215429